Elisabet Coll

Elisabet Coll

Auto-generated profile, based on publicly available information

Elisabet Coll

Nephrology Department, Fundació Puigvert, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2000 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
ECElisabeth Coll
Elisabeth Coll
ABAlbert Botey
Albert Botey
LALuisa Alvarez
Luisa Alvarez
EPEsteban Poch
Esteban Poch
LQLlorenç Quintó
Llorenç Quintó
ADAlejandro Darnell
Alejandro Darnell

1 December 2005 in Kidney International
Verified
Journal Article
Closed access
ACAleix Cases
Aleix Cases
ECElisabet Coll
Elisabet Coll

1 June 1998 in Kidney International
Verified
Journal Article
Closed access
PFPatricia Fernández-Llama
Patricia Fernández-Llama
EPEsteban Poch
Esteban Poch
JOJosep Oriola
Josep Oriola
ABAlbert Botey
Albert Botey
ECElisabet Coll
Elisabet Coll
LRLuis Revert
Luis Revert

4 November 2009 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
ESElitsa Stoyanova
Elitsa Stoyanova
SSSilvia Berenice Sandoval
Silvia Berenice Sandoval
LZLiliana Andrea Zúñiga
Liliana Andrea Zúñiga
NENaouale El-Yamani
Naouale El-Yamani
ECElisabet Coll
Elisabet Coll
RMRicard Marcos
Ricard Marcos
Background: Chronic renal failure (CRF) patients present a high incidence of cardiovascular pathologies and cancer. This has been attributed to the existence of genomic instability in these patients, and consequently they should present elevated levels of genetic damage. Methods: To determine the background levels of genetic damage and its specific levels of oxidative damage, a large population of 253 CRF patients (77 in dialysis) was analysed using the comet assay. The percentage of DNA in the tail was used as a measure of basal genetic damage. In addition, the use of endo III and FPG enzymes allowed us to determine the levels of specific oxidative damage in DNA bases. Results: This is the first study that uses endo III and FPG enzymes to measure oxidative damage in CRF patients. Overall genetic damage, as well as specific oxidative damage, was higher in dialysis patients than in the CRF patients with different stages of uraemic state; genetic damage increased when serum creatinine levels increased. Genomic damage in dialysis patients decreased in those patients submitted to dialysis for a long time. Conclusions: Genetic damage increases when renal function decreases, being maximum in haemodialysis patients. Although part of the observed damage can be attributed to the uraemic state itself, other individual genetic factors can influence a state of genomic instability responsible for the observed genomic damage.

1 March 2017 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
LRLara Rodríguez-Ribera
Lara Rodríguez-Ribera
ZCZuray Corredor
Zuray Corredor
ISIrene Silva
Irene Silva
JDJuan Manuel Díaz
Juan Manuel Díaz
JBJosé Ballarín
José Ballarín
ECElisabet Coll
Elisabet Coll

30 September 2010 in Mutagenesis
Verified
Journal Article
Open access
PDF file
SSSilvia Berenice Sandoval
Silvia Berenice Sandoval
ESElitsa Stoyanova
Elitsa Stoyanova
ECElisabet Coll
Elisabet Coll
SPSusana Pastor
Susana Pastor
JRJoselyn Reyes
Joselyn Reyes
RMRicard Marcos
Ricard Marcos
Chronic renal failure (CRF) patients are considered to present genomic instability and, as a consequence, elevated levels of genetic damage. An open question is whether this damage is related to the stage of the pathology. To determine the background levels of genetic damage, a large population of 258 Caucasian adults (201 CRF patients and 57 controls) was analysed using the micronucleus (MN) assay. The frequency of MN in CRF patients was significantly higher than in controls and correlated with the progression of the disease, according to the glomerular filtration rate. In addition, a significant association was observed between genetic damage and serum creatinine levels. Genetic damage, measured as frequency of MN, increases when renal function decreases. The fact that an increased level of MN is already observed in patients’ Stage 2 seems to indicate a genetic predisposition on these patients. Nevertheless, part of the observed damage can be attributed to the uraemic state itself.